We shouldn’t underestimate the value to BP of our research projects, either. Triebel understands Lag3 inside out and backwards. Our work with Monash and Cardiff in terms of future directions in Lag3 would be priceless in the space, simply because of Triebel’s direction.
If a larger pharma wanted to get on the front edge of Lag3 they would take us out, no question. They wouldn’t even need to be one of the big guns.
With Lag3 on the cusp of FDA approval. Now would probably be the worst time in Immutep history to sell shares
Just my opinion only.
We shouldn’t underestimate the value to BP of our research...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
-0.010(2.94%) |
Mkt cap ! $480.0M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 33.5¢ | 32.0¢ | $1.703M | 5.215M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 211685 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 279000 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |